Author

D. Nishizaki

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Targeted Therapies, Biologics, and Immunotherapy in the Neoadjuvant and Adjuvant Settings: Perioperative Risks.

Cancer therapeutics has been revolutionized by the introduction of molecularly targeted therapies and immune checkpoint inhibitors (ICIs). The paradigm of neoadjuvant therapy is commonly employed across multiple solid tumors, exhibiting significant clinical benefit as exemplified with ICIs in melanoma and non-small-cel...

D. Nishizaki, R. N. Eskander · Hematology/Oncology Clinics... · 0 citations

Sep 2026

Abstract B107: Peptide-delivered low dose IL-2 reprograms pancreatic cancer immunity to improve survival

Metastatic pancreatic cancer (PC) has a dismal 5-year survival rate of 2% due to limited chemotherapy, lack of immunotherapy options, and high drug resistance. The tumor-immune microenvironment (TIME) in PC, marked by dense desmoplasia, inactive anti-cancer T-cells, and immunosuppressive regulatory T-cells (Tregs...

In Hwan Park, G. Botta, Shawn A. Abeynaike et al. · Cancer Research · 0 citations

Sep 2026

Abstract B075: Harnessing Tumor-Penetrating Peptides to Modulate the Pancreatic Tumor Immune Microenvironment

Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of approximately 13% and remains largely resistant to immunotherapy because its dense fibrotic stroma restricts drug penetration, and its immunosuppressive tumor microenvironment (TME) limits anti-tumor immunity. Novel strategies are urgently needed t...

Shawn A. Abeynaike, In Hwan Park, Ashley Martinez et al. · Cancer Research · 0 citations